Want to see IN:GUFICBIO full AI Analyst Report?
GUFICBIO Stock Chart & Stats
₹378.25
₹3.40(0.90%)
At close: 4:00 PM EDT
₹378.25
₹3.40(0.90%)
Day’s Range― - ―
52-Week Range₹267.50 - ₹466.05
Previous CloseN/A
Volume48.22K
Average Volume (3M)4.04K
Market Cap
₹40.65B
Enterprise Value₹30.82B
Total Cash (Recent Filing)₹621.86M
Total Debt (Recent Filing)₹0.00
Price to Earnings (P/E)53.2
Beta0.70
Next Earnings
Nov 12, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield0.03%
Share Statistics
EPS (TTM)7.32
Shares Outstanding100,282,510
10 Day Avg. Volume3,142
30 Day Avg. Volume4,036
Financial Highlights & Ratios
PEG Ratio-5.32
Price to Book (P/B)4.13
Price to Sales (P/S)2.91
P/FCF Ratio-152.53
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Pharmaceutical Portfolio And Market ReachA diversified formulation portfolio across therapeutic areas, including injectable products, gives Gufic multiple avenues to serve domestic and international demand. Manufacturing and marketing capabilities can support recurring product sales and broaden opportunities beyond any single medicine or market.
Positive Revenue GrowthRevenue growth re-accelerated in FY2026 after a flat prior year, indicating that the business regained some top-line momentum. Continued sales expansion would improve operating leverage, support investment in products and capacity, and strengthen the company’s ability to compound earnings.
Manageable Leverage And Growing EquityLeverage remains manageable and debt-to-equity has improved materially from FY2023, while equity growth supports asset expansion. Positive return on equity indicates the capital base is still producing profits, preserving some capacity to fund operations and growth.
Bears Say
Weak And Volatile Cash GenerationThe sharp deterioration in operating cash flow and negative free cash flow show that reported earnings are not converting reliably into cash. Persistent volatility can constrain reinvestment, increase reliance on financing, and reduce resilience when working-capital or investment needs rise.
Margin And Profit CompressionAlthough profitability remains positive, lower gross and operating margins versus FY2023–FY2024 and declining net income indicate weaker earnings conversion. If this persists, the company may have less internal funding for product development, expansion, and balance-sheet strengthening.
Declining Returns And Reduced FlexibilityThe combination of lower returns on equity and debt that remains above earlier FY2021–FY2022 levels weakens financial flexibility. Less efficient use of capital can limit funding choices and make it harder to absorb operational setbacks while sustaining expansion.
Gufic Biosciences Limited News
GUFICBIO FAQ
What was Gufic Biosciences Limited’s price range in the past 12 months?
Gufic Biosciences Limited lowest stock price was ₹267.50 and its highest was ₹466.05 in the past 12 months.
What is Gufic Biosciences Limited’s market cap?
Gufic Biosciences Limited’s market cap is ₹40.65B.
When is Gufic Biosciences Limited’s upcoming earnings report date?
Gufic Biosciences Limited’s upcoming earnings report date is Nov 12, 2026 which is in 20 days.
How were Gufic Biosciences Limited’s earnings last quarter?
Gufic Biosciences Limited released its earnings results on Aug 14, 2026. The company reported ₹2.225 earnings per share for the quarter.
Is Gufic Biosciences Limited overvalued?
According to Wall Street analysts Gufic Biosciences Limited’s price is currently Overvalued.
Does Gufic Biosciences Limited pay dividends?
Gufic Biosciences Limited pays a Annually dividend of ₹0.1 which represents an annual dividend yield of 0.03%. See more information on Gufic Biosciences Limited dividends here
What is Gufic Biosciences Limited’s EPS estimate?
Gufic Biosciences Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Gufic Biosciences Limited have?
Gufic Biosciences Limited has 100,282,510 shares outstanding.
What happened to Gufic Biosciences Limited’s price movement after its last earnings report?
Gufic Biosciences Limited reported an EPS of ₹2.225 in its last earnings report. Following the earnings report the stock price went down -2.285%.
Which hedge fund is a major shareholder of Gufic Biosciences Limited?
Currently, no hedge funds are holding shares in IN:GUFICBIO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Gufic Biosciences Limited
Gufic Biosciences Limited is an Indian enterprise dedicated to the manufacturing and marketing of active pharmaceutical ingredients (APIs), generic medications, and related support services. The company's API and bulk drug offerings include antifungals, anesthetics, immunosuppressants, and intermediates for antifungal treatments. It also produces lyophilized injectable pharmaceuticals, covering diverse therapeutic areas such as antibiotics, antifungals, cardiac care, infertility solutions, antivirals, and proton-pump inhibitors. Additionally, Gufic Biosciences provides pharmaceutical products under its Spark, Criti Care, and Ferti Care brands, as well as a line of herbal and personal care items. The company distributes its extensive product portfolio to hospital networks and medical facilities, and it exports its goods to over twenty countries globally. Established in 1970, Gufic Biosciences Limited is headquartered in Mumbai, India.
Technical Analysis
Bliss Gvs Pharma Limited
―
Indoco Remedies Limited
―
Morepen Laboratories Limited
―
Orchid Pharma Limited
―
Unichem Laboratories Limited
―